Pfizer (NYSE:PFE) received a $40.00 target price from research analysts at UBS in a research report issued to clients and investors on Wednesday, www.boersen-zeitung.de reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. UBS’s price target suggests a potential upside of 12.01% from the stock’s previous close.

A number of other brokerages also recently commented on PFE. Cowen set a $43.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research note on Monday, August 14th. Jefferies Group set a $35.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a research note on Thursday, August 24th. Berenberg Bank restated a “hold” rating and issued a $36.00 price objective (down previously from $39.00) on shares of Pfizer in a research note on Tuesday, August 15th. Deutsche Bank set a $38.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research note on Wednesday, October 11th. Finally, Goldman Sachs Group set a $36.00 price objective on shares of Pfizer and gave the company a “neutral” rating in a research note on Wednesday, November 1st. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $38.77.

Shares of Pfizer (PFE) traded up $0.08 during mid-day trading on Wednesday, hitting $35.71. 2,072,272 shares of the company were exchanged, compared to its average volume of 19,989,418. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $214,943.11, a P/E ratio of 14.42, a P/E/G ratio of 2.54 and a beta of 1.01. Pfizer has a 12-month low of $30.51 and a 12-month high of $36.78.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.02. The firm had revenue of $13.17 billion during the quarter, compared to the consensus estimate of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The company’s revenue was up .9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.61 earnings per share. equities analysts expect that Pfizer will post 2.59 earnings per share for the current fiscal year.

In other news, EVP Alexander R. Mackenzie sold 7,350 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $35.65, for a total value of $262,027.50. Following the completion of the sale, the executive vice president now directly owns 117,432 shares of the company’s stock, valued at $4,186,450.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Sally Susman sold 38,230 shares of the company’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the completion of the sale, the insider now directly owns 145,649 shares of the company’s stock, valued at $5,097,715. The disclosure for this sale can be found here. Insiders sold 60,280 shares of company stock valued at $2,118,988 over the last ninety days. Corporate insiders own 0.06% of the company’s stock.

Several large investors have recently made changes to their positions in the company. Norges Bank acquired a new stake in shares of Pfizer in the fourth quarter valued at approximately $1,896,890,000. Emerald Acquisition Ltd. acquired a new stake in shares of Pfizer in the second quarter valued at approximately $555,074,000. Alliancebernstein L.P. grew its position in shares of Pfizer by 31.9% in the fourth quarter. Alliancebernstein L.P. now owns 55,389,458 shares of the biopharmaceutical company’s stock valued at $1,787,972,000 after purchasing an additional 13,407,250 shares during the last quarter. Russell Investments Group Ltd. acquired a new stake in shares of Pfizer in the fourth quarter valued at approximately $384,874,000. Finally, Corvex Management LP grew its position in shares of Pfizer by 844.6% in the fourth quarter. Corvex Management LP now owns 12,414,348 shares of the biopharmaceutical company’s stock valued at $400,735,000 after purchasing an additional 11,100,098 shares during the last quarter. 69.89% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This article was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/12/06/ubs-reiterates-40-00-price-target-for-pfizer-pfe.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.